Biomarkers of Vascular Disease Progression in Type 1 Diabetes Mellitus

1 型糖尿病血管疾病进展的生物标志物

• 批准号: 8119775
• 负责人: MARIA F LOPES-VIRELLA
• 金额: $ 39.51万
• 依托单位: MEDICAL UNIVERSITY OF SOUTH CAROLINA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2013-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8119775
• 关键词: Algorithms; Alteplase; Biological Assay; Biological Markers; Blood Vessels; Coagulation Process; Complication; Complications of Diabetes Mellitus; Development; Diabetes Mellitus; Disease Progression; E-Selectin; Endothelial Cells; Enrollment; Fibrinogen; Functional disorder; Glycosylated hemoglobin A; Goals; Hypertension; Inflammation; Insulin-Dependent Diabetes Mellitus; Intercellular adhesion molecule 1; Interleukin-6; Lipids; Measurement; Measures; Metabolic; Patients; Phase; Plasma; Plasminogen Activator Inhibitor 1; Predictive Value; Research; Research Personnel; Risk; Risk Factors; Sampling; Secondary to; Smoking; System; TNF gene; TNFR-Fc fusion protein; Vascular Cell Adhesion Molecule-1; Vascular Diseases; arm; cohort; follow-up; glycemic control; high risk; imprint; macrovascular disease; novel; receptor

DESCRIPTION (provided by applicant): The goal of the proposed research is to elucidate the value of selected biomarkers in predicting the development of micro- and macro-vascular complications in Type 1 diabetes and to determine if several risk factors, some unique to diabetes, may interact to augment vascular risk. We will measure three classes of biomarkers: i.) endothelial cell dysfunction - soluble ICAM-1, VCAM, and E selectin; ii.) inflammation-interleukin-6, CRP, and soluble TNF ?receptors; iii.) fibrinolytic and clotting system - fibrinogen, plasminogen activator inhibitor-1 and tissue plasminogen activator. We will assay these biomarkers longitudinally in samples, obtained from the well characterized DCCT/EDIC cohort of type 1 diabetes, at the DCCT baseline and closeout phases, and in years 3-5 and 9-12 of the EDIC phase of the study. We hypothesize that the pathogenic interaction between inflammation and endothelial cell/clotting/fibrinolytic dysfunction greatly contributes to the accelerated development of vascular complications in diabetes, and that selective clustering of the above biomarkers will predict patients at high risk to develop complications. Furthermore, we also hypothesize that the persistent, lower rate of complications observed in patients enrolled in the intensive glycemic control arm of the DCCT study even 10 years after the close-out of the DCCT is secondary to the effect of sustained glycemic control in one or more of the biomarkers we propose to measure. We will evaluate this hypothesis in three aims. Aim 1 will determine if concentrations of any biomarker or cluster of biomarkers, will predict the development of micro- or macro-vascular complications in this cohort and whether they predict a select group of complications, all vascular complications, or a single complication. Aim 2 will assess if levels of any of the biomarkers studied that remain similar, during the EDIC phase of the study, to those measured at DCCT close-out can explain the slower progression of complications observed in patients enrolled in the intensive glycemic control arm of the DCCT/EDIC study over the next decade of follow-up and, therefore, explain the "metabolic imprint" phenomenon postulated by the DCCT/EDIC group of investigators. Aim 3 will assess the value of the panel of novel biomarkers identified in Aim 1 to predict diabetic complications by assaying these biomarkers in samples collected at entry into the DCCT trial from patients not used to construct the biomarker risk algorithm.

描述（由申请人提供）：拟议研究的目标是阐明选定的生物标志物在预测1型糖尿病微血管和大血管并发症发展中的价值，并确定几种风险因素（其中一些是糖尿病特有的）是否可能相互作用，增加血管风险。我们将测量三类生物标志物：内皮细胞功能障碍-可溶性ICAM-1、VCAM和E选择素; ii.）炎症-白细胞介素-6，CRP和可溶性TNF？受体; iii.）纤维蛋白溶解和凝血系统-纤维蛋白原、纤溶酶原激活物抑制剂-1和组织纤溶酶原激活物。我们将在DCCT基线和结束阶段以及研究EDIC阶段的第3-5年和第9-12年从充分表征的DCCT/EDIC 1型糖尿病队列中获得的样本中纵向分析这些生物标志物。我们假设炎症和内皮细胞/凝血/纤溶功能障碍之间的致病性相互作用极大地促进了糖尿病血管并发症的加速发展，并且上述生物标志物的选择性聚类将预测具有发生并发症高风险的患者。此外，我们还假设，即使在DCCT关闭后10年，在DCCT研究的强化血糖控制组入组的患者中观察到的持续、较低的并发症发生率继发于我们建议测量的一种或多种生物标志物的持续血糖控制效果。我们将从三个方面来评估这一假设。目标1将确定任何生物标志物或生物标志物簇的浓度是否将预测该队列中微血管或大血管并发症的发展，以及它们是否预测选定的并发症组、所有血管并发症或单一并发症。目标2将评估在研究的EDIC阶段期间，与DCCT结束时测量的水平保持相似的任何研究的生物标志物的水平是否可以解释在接下来的十年随访中，在DCCT/EDIC研究的强化血糖控制组中入组的患者中观察到的并发症进展较慢，因此，解释DCCT/EDIC研究小组假设的“代谢印记”现象。目标3将通过分析进入DCCT试验时从未用于构建生物标志物风险算法的患者中收集的样本中的这些生物标志物，评估目标1中确定的一组新型生物标志物预测糖尿病并发症的价值。

项目成果

Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications.

• DOI: 10.3390/ijms241814015
• 发表时间: 2023-09-13
• 期刊: International journal of molecular sciences
• 影响因子: 5.6

Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323.

对 Lopes-Virella 等人的评论的回应

• DOI: 10.2337/dc13-2976
• 发表时间: 2014
• 期刊: Diabetes care
• 影响因子: 16.2
• 作者: Lopes-Virella,MariaF;Baker,NathanielL;Hunt,KellyJ;Cleary,PatriciaA;Klein,Richard;Virella,Gabriel;DCCT/EDICResearchGroup
• 通讯作者: DCCT/EDICResearchGroup